Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1958 1
1962 2
1965 3
1967 1
1968 2
1969 2
1970 3
1971 3
1972 2
1973 4
1974 2
1975 3
1977 3
1978 1
1980 2
1981 1
1982 3
1983 1
1984 2
1985 1
1986 2
1987 2
1988 1
1989 2
1990 4
1991 4
1992 2
1993 5
1994 4
1995 2
1996 7
1997 9
1998 9
1999 9
2000 11
2001 20
2002 19
2003 24
2004 11
2005 15
2006 22
2007 19
2008 16
2009 18
2010 15
2011 21
2012 23
2013 26
2014 21
2015 28
2016 29
2017 19
2018 23
2019 27
2020 30
2021 37
2022 37
2023 28
2024 13

Text availability

Article attribute

Article type

Publication date

Search Results

604 results

Results by year

Filters applied: . Clear all
The following term was not found in PubMed: Todagbe
Page 1
Did you mean godambe as[au] (3 results)?
UK 2022 Consensus on Normal Tissue Dose-Volume Constraints for Oligometastatic, Primary Lung and Hepatocellular Carcinoma Stereotactic Ablative Radiotherapy.
Diez P, Hanna GG, Aitken KL, van As N, Carver A, Colaco RJ, Conibear J, Dunne EM, Eaton DJ, Franks KN, Good JS, Harrow S, Hatfield P, Hawkins MA, Jain S, McDonald F, Patel R, Rackley T, Sanghera P, Tree A, Murray L. Diez P, et al. Among authors: van as n. Clin Oncol (R Coll Radiol). 2022 May;34(5):288-300. doi: 10.1016/j.clon.2022.02.010. Epub 2022 Mar 7. Clin Oncol (R Coll Radiol). 2022. PMID: 35272913
UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy.
Hanna GG, Murray L, Patel R, Jain S, Aitken KL, Franks KN, van As N, Tree A, Hatfield P, Harrow S, McDonald F, Ahmed M, Saran FH, Webster GJ, Khoo V, Landau D, Eaton DJ, Hawkins MA. Hanna GG, et al. Among authors: van as n. Clin Oncol (R Coll Radiol). 2018 Jan;30(1):5-14. doi: 10.1016/j.clon.2017.09.007. Epub 2017 Oct 13. Clin Oncol (R Coll Radiol). 2018. PMID: 29033164 Free article.
Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial.
Tree AC, Ostler P, van der Voet H, Chu W, Loblaw A, Ford D, Tolan S, Jain S, Martin A, Staffurth J, Armstrong J, Camilleri P, Kancherla K, Frew J, Chan A, Dayes IS, Duffton A, Brand DH, Henderson D, Morrison K, Brown S, Pugh J, Burnett S, Mahmud M, Hinder V, Naismith O, Hall E, van As N; PACE Trial Investigators. Tree AC, et al. Among authors: van as n. Lancet Oncol. 2022 Oct;23(10):1308-1320. doi: 10.1016/S1470-2045(22)00517-4. Epub 2022 Sep 13. Lancet Oncol. 2022. PMID: 36113498 Free article. Clinical Trial.
Salvage stereotactic body radiotherapy (SBRT) for intraprostatic relapse after prostate cancer radiotherapy: An ESTRO ACROP Delphi consensus.
Jereczek-Fossa BA, Marvaso G, Zaffaroni M, Gugliandolo SG, Zerini D, Corso F, Gandini S, Alongi F, Bossi A, Cornford P, De Bari B, Fonteyne V, Hoskin P, Pieters BR, Tree AC, Arcangeli S, Fuller DB, Franzese C, Hannoun-Levi JM, Janoray G, Kerkmeijer L, Kwok Y, Livi L, Loi M, Miralbell R, Pasquier D, Pinkawa M, Scher N, Scorsetti M, Shelan M, Toledano A, van As N, Vavassori A, Zilli T, Pepa M, Ost P; on the behalf of the European Society for Radiotherapy, Oncology Advisory Committee on Radiation Oncology Practice (ESTRO ACROP). Jereczek-Fossa BA, et al. Among authors: van as n. Cancer Treat Rev. 2021 Jul;98:102206. doi: 10.1016/j.ctrv.2021.102206. Epub 2021 Apr 20. Cancer Treat Rev. 2021. PMID: 33965893 Review.
Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial.
Brand DH, Tree AC, Ostler P, van der Voet H, Loblaw A, Chu W, Ford D, Tolan S, Jain S, Martin A, Staffurth J, Camilleri P, Kancherla K, Frew J, Chan A, Dayes IS, Henderson D, Brown S, Cruickshank C, Burnett S, Duffton A, Griffin C, Hinder V, Morrison K, Naismith O, Hall E, van As N; PACE Trial Investigators. Brand DH, et al. Among authors: van as n. Lancet Oncol. 2019 Nov;20(11):1531-1543. doi: 10.1016/S1470-2045(19)30569-8. Epub 2019 Sep 17. Lancet Oncol. 2019. PMID: 31540791 Free PMC article. Clinical Trial.
Nipah Virus Infection.
Av R, Sadanandan S, Thulaseedharan NK, Kg SK, Pallivalappil B, As AK. Av R, et al. Among authors: as ak. J Assoc Physicians India. 2018 Dec;66(12):58-60. J Assoc Physicians India. 2018. PMID: 31313551
Surgical challenges in Limpopo.
Van As AB, Mhlongo TF. Van As AB, et al. S Afr Med J. 2021 Dec 1;111(11b):13449. doi: 10.7196/SAMJ.2021.v111i11b.16097. S Afr Med J. 2021. PMID: 34949231
Management of paediatric liver trauma.
van As AB, Millar AJ. van As AB, et al. Pediatr Surg Int. 2017 Apr;33(4):445-453. doi: 10.1007/s00383-016-4046-3. Epub 2016 Dec 27. Pediatr Surg Int. 2017. PMID: 28028561 Review.
Response to letter from Prof. Hedayati.
Van As BAL, Nocentini A, Menesini E. Van As BAL, et al. Int Psychogeriatr. 2022 Dec;34(12):1059-1060. doi: 10.1017/S1041610222000916. Int Psychogeriatr. 2022. PMID: 36484378 No abstract available.
604 results